Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
652.90B
Market cap652.90B
Price-Earnings ratio
40.76
Price-Earnings ratio40.76
Dividend yield
1.96%
Dividend yield1.96%
Average volume
7.56M
Average volume7.56M
High today
$274.61
High today$274.61
Low today
$264.20
Low today$264.20
Open price
$265.83
Open price$265.83
Volume
6.39M
Volume6.39M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$184.66
52 Week low$184.66

Stock Snapshot

With a market cap of 652.9B, Johnson & Johnson(JNJ) trades at $273.84. The stock has a price-to-earnings ratio of 40.76 and currently yields dividends of 1.96%.

As of 2026-10-28, Johnson & Johnson(JNJ) stock has fluctuated between $264.20 and $274.61. The current price stands at $273.84, placing the stock +3.6% above today's low and -0.3% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 6.39M, compared to an average daily volume of 7.56M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

JNJ News

New York Times 8h
Bo Nix’s family took in high school teammate Tez Johnson. Then came an ‘absolute miracle’ - The New York Times

...

Bo Nix’s family took in high school teammate Tez Johnson. Then came an ‘absolute miracle’ - The New York Times
Simply Wall St 14h
Johnson & Johnson Shows Over 75% Response Rates In Two Cancer Trials

Johnson & Johnson (NYSE: JNJ) reported new clinical data on JNJ-6143 and RYBREVANT FASPRO in advanced cancers on 26 October 2026. JNJ-6143, built on the RIPTAC...

24/7 Wall St. 1d
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks

Investing Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks Medtronic's 49-year dividend streak sounds impressive until yo...

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
25.9%
Sell
7.4%

More JNJ News

24/7 Wall St. 1d
Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?

Investing Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors? Medtronic just extended a nearly half-century dividend streak, but its...

Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?
24/7 Wall St. 2d
Forget Chasing High Yields: These 4 Dividend Kings Play the Long Game

Investing Forget Chasing High Yields: These 4 Dividend Kings Play the Long Game Fifty-plus years of unbroken dividend raises sounds impressive until you ask whe...

Forget Chasing High Yields: These 4 Dividend Kings Play the Long Game
Simply Wall St 3d
Is Prostate Cancer Trial Success Altering The Investment Case For J&J?

Johnson & Johnson reported fresh oncology data, including Phase 3 PROTEUS results where apalutamide plus ADT improved event free survival versus surgery alone i...

TipRanks 3d
Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026

Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The result...

The Motley Fool 4d
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Income seekers and growth investors often choose between biotech pioneers and diversified pharmaceutical giants. Comparing Amgen (AMGN -1.79%) and Johnson & Joh...

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
Simply Wall St 5d
Johnson & Johnson Unveiled Fresh Cardiology Data, Is The Stock Fully Valued?

Johnson & Johnson (JNJ) is back in focus after fresh data from its VARIPURE and Omny-IRE studies on pulsed field ablation were unveiled at the APHRS 2026 cardio...

24/7 Wall St. 6d
Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up

Investing Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up Procter & Gamble is surging on a str...

Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.